Cantor Fitzgerald initiated coverage on Veradermics
$MANE
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Veradermics with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2026 | Overweight | Cantor Fitzgerald | |
| 3/2/2026 | $85.00 | Buy | Citigroup |
| 3/2/2026 | $75.00 | Buy | Jefferies |
| 3/2/2026 | $75.00 | Outperform | Leerink Partners |
4/A - Veradermics, Inc (0001827635) (Issuer)
4 - Veradermics, Inc (0001827635) (Issuer)
3 - Veradermics, Inc (0001827635) (Issuer)
Cantor Fitzgerald initiated coverage of Veradermics with a rating of Overweight
Jefferies initiated coverage of Veradermics with a rating of Buy and set a new price target of $75.00
Citigroup initiated coverage of Veradermics with a rating of Buy and set a new price target of $85.00
Enrollment completed in two pivotal trials of VDPHL01 in male patients; topline data expected from Study 302 in 1H 2026 and Study 304 confirmatory trial in 2H 2026 Enrollment on-track in Study 306, the first-ever Phase 2/3 trial of an oral treatment specifically for female pattern hair loss Mark Neumann, seasoned biopharmaceutical commercial leader with more than 30 years of experience launching and scaling blockbuster therapies, appointed Chief Commercial and Strategy Officer Upsized IPO of $294.8 million closed in February 2026; pro forma cash, cash equivalents and marketable securities expected to fund planned operations into 2029, through multiple anticipated Phase 3 readouts and
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held in Denver, Colorado on March 27 – 31, 2026. The data to be presented include a blinded, retrospective investigator global assessment conducted by six independent dermatologists regarding the comparative perceived efficacy of VDPHL01 versus existing minoxidil formulations and the clinical potential of VDPHL01. In addition, two presentations will characteriz
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March: Leerink Partners Global Healthcare Conference on Tuesday, March 10 in Miami, FL Reid Waldman, M.D., CEO of Veradermics, will participate in a fireside chat at 4:20 p.m. ET. Jefferies Biotech on the Beach Summit on Wednesday, March 11 in Miami, FL A live webcast of the Leerink conference fireside chat will be available on the "Events" page of the "Investors" section of the
4/A - Veradermics, Inc (0001827635) (Issuer)
4 - Veradermics, Inc (0001827635) (Issuer)
4 - Veradermics, Inc (0001827635) (Issuer)
10-K - Veradermics, Inc (0001827635) (Filer)
8-K - Veradermics, Inc (0001827635) (Filer)
SCHEDULE 13G - Veradermics, Inc (0001827635) (Subject)